XIANYANG, China, June 21, 2011 /PRNewswire-Asia-FirstCall/ -- BioStar Pharmaceuticals, Inc. (NASDAQ GM: BSPM) ("BioStar" or "the Company"), a Xianyang-based manufacturer of a leading PRC over-the-counter Hepatitis B medicine, Xin Aoxing Oleanolic Acid Capsules and a variety of pharmaceutical products, today announced that Mr. Ronghua Wang, Chief Executive Officer and Chairman of the Board of Directors of the Company, and Mr. Zack Pan, Chief Financial Officer of the Company, will attend the Brean Murray, Carret & Co 2011 Beijing China Growth Conference on June 27-28, 2011 at the JW Marriott Hotel, Beijing, China.
Both Mr. Wang and Mr. Pan will be available to meet with investors throughout the conference, to schedule a meeting or if you have any questions relating to the conference, please send an email to biostar@fleishman.com or contact your Brean Murray, Carret & Co. representative directly.
About BioStar Pharmaceuticals, Inc.
Biostar Pharmaceuticals, Inc., through its wholly-owned subsidiary and controlled affiliate in China, develops, manufactures and markets pharmaceutical and health supplement products for a variety of diseases and conditions. The Company's most popular product is its Xin Ao Xing Oleanolic Acid Capsule, an over-the-counter ("OTC") medicine for chronic hepatitis B, a disease affecting approximately 10% of the Chinese population. In addition to its hepatitis product, Biostar currently manufactures two broad-based OTC products, two prescription-based pharmaceuticals, one medical device and five health supplements. For more information please visit: http://www.biostarpharmaceuticals.com
Cautionary Note re: Forward Looking Statements
Statements contained in this communication not relating to historical facts are forward-looking statements that are intended to fall within the safe harbor rule for such statements under the Private Securities Litigation Reform Act of 1995. Actual results may differ materially from those indicated by these forward-looking statements as a result of various important factors. Such risks, uncertainties, and other factors include, but are not necessarily limited to, those set forth under the caption "Item 1A. Risk Factors" in Biostar's most recent Annual Report on Form 10-K filing, as amended to date, and to the extent revised and updated to date in its subsequent Form 10-Q filings. In addition, Biostar operates in a highly competitive and rapidly changing environment, and new risks may arise. Accordingly, you should not place any reliance on forward-looking statements as a prediction of actual results. Biostar disclaims any intention to, and undertakes no obligation to, update or revise any forward-looking statement. You are also urged to carefully review and consider the various disclosures in Biostar's most recent public reports filed with the SEC.
|
Investor Relations contact: |
|
|
BioStar Pharmaceuticals, Inc. |
|
|
Zack Pan, CFO |
|
|
T: +1-405-996-8829 |
|
|
E: zpan@aoxing-group.com |
|
|
Fleishman-Hillard |
|
|
T: +852-2530-0228 |
|
|
E: biostar@fleishman.com |
|